Back grey_arrow_rt.gif
 
Recent articles on HIV.
 
null.gif
 
 
  1. Tibotec Launches Email/Text Message Adherence Program
     
  2. Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture - (07/04/08)
     
  3. Use of Antidepressants and Rates of Hip Bone Loss in Older Women - (07/04/08)
     
  4. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis (increased 13% risk): A systematic review - (07/02/08)
     
  5. Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population: high rates of improved mortality among HIV diagnosed - (07/02/08)
     
  6. Fracture Prevalence Among HIV-Infected versus Non HIV-Infected Patients in a Large U.S. Healthcare System - (07/02/08)
     
  7. Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome - (07/01/08)
     
  8. Low HDL Cholesterol Is a Risk Factor for Deficit and Decline in Memory in Midlife. The Whitehall II Study - (07/01/08)
     
  9. Low Levels Of Good Cholesterol Linked To Memory Loss, Dementia Risk - (07/01/08)
     
  10. Important FDA Label changes to Viramune (nevirapine) oral solution and tablets - (06/30/08)
     
  11. Antiretroviral Therapy is Associated With an Atherogenic Lipoprotein Phenotype Among HIV-1-Infected Men in the Multicenter AIDS Cohort Study - (06/27/08)
     
  12. Prevalence and Predictors of Metabolic Syndrome Among HIV-Infected and HIV-Uninfected Women in the Women's Interagency HIV Study: metabolic syndrome 50% in HIV+ women - (06/27/08)
     
  13. Kidney and Bladder Cancers Among People With AIDS in the United States - (06/27/08)
     
  14. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes - (06/27/08)
     
  15. New pediatric dosing information for Kaletra, patients 14 days to 6 months and 12-18 years of age and update information on coadministration with midazolam - (06/24/08)
     
  16. European Commission Approves REYATAZ(R) (Atazanavir Sulfate 100mg, 150mg, 200mg, 300mg), in Combination With Other Antiretroviral Medicinal Products, for use in Treatment Naive HIV-1 Infected Adults - (06/24/08)
     
  17. CVD is a "Major Killer" in HIV+ Patients, but Underrecognized by Doctors. Complicated interplay between risks from anti-HIV drugs, risks from virus itself, and traditional risk factors which tend to be prevalent among HIV-infected - (06/24/08)
     
  18. ResisWksp: Low frequency K103N mutations are strongly associated with inadequate virologic responses to NNRTI-based therapy. sdNVP & K103N - (06/26/08)
     
  19. ResisWksp: Identifying Low-Level CXCR4 Virus with Roche 454 Life Sciences Sensitive Assay - (06/25/08)
     
  20. ResisWksp: Comparable in-vitro susceptibility and virological outcome to darunavir in patients infected with subtype B and non-subtype B HIV isolates participating in the ARTEMIS Phase III trial - (06/25/08)
     
  21. ResisWksp: Detection of Low Abundance Drug Resistant HIV Variants in Treatment Experienced Subjects by Ultra Deep Sequencing (454 Life Sciences/Roche Test) - (06/25/08)
     
  22. ResisWksp: NNRTI Resistance in Naives 16%. Changes in Regional Prevalence, Clade and Epidemiology of HIV-1 Drug Resistance Mutations and Clade among Antiviral Therapy-Naive Patients in the United States (US) from 2000 to 2007 - (06/25/08)
     
  23. Weight Gain Increases Risk for Kidney Disease - (06/24/08)
     
  24. ResisWksp: HIV-1 resistance in Mozambican infants following prophylaxis with single-dose nevirapine (sdNVP) - (06/24/08)
     
  25. ResisWksp: Report on the XV11 International Drug Resistance Workshop, June 10-14, 2008, Sitges, Spain - Written by Mark A Wainberg - (06/24/08)
     
  26. ResisWksp: Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens - (06/24/08)
     
  27. ResisWksp: Antiretroviral Intensification Does Not Reduce HIV-1 Viremia in Patients Suppressed on Standard Combination Therapy - (06/24/08)
     
  28. ResisWksp: No effect of subtype on susceptibility and virologic response to TPV/r for treatment experienced patients - (06/24/08)
     
  29. ResisWksp: Mutations 24I, 50L/V, 54L, and 76V, selected by other protease inhibitors, predict durable response to tipranavir in treatment experienced patients when two or more are present - (06/24/08)
     
  30. ResisWksp: Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays - (06/23/08)
     
  31. ResisWksp: Technical Validation of an Enhanced Sensitivity Trofile HIV Co-receptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5 - (06/23/08)
     
  32. ResisWksp: Virological Response and Resistance in Multi-Experienced Patients Treated with Raltegravir - (06/20/08)
     
  33. ResisWksp: Slightly Revised Darunavir Resistance Profile from Tibotec - (06/20/08)
     
  34. ResisWksp: Virologic and Immunologic Outcomes in a Cohort of Subjects Failing Integrase Inhibitors - (06/20/08)
     
  35. ResisWksp: Tibotec Analysis: Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR) - (06/20/08)
     
  36. ResisWksp: Monogram Analysis: Loss of Raltegravir Susceptibility in Treated Patients is Conferred by Multiple Non-overlapping Genetic Pathways - (06/20/08)
     
  37. ResisWksp: Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naive and adherent patients - (06/20/08)
     
  38. ResisWksp: Tibotec Etravirine Weighted Genotype Score to Predict Response - (06/20/08)
     
  39. ResisWksp: Resistance Mutations in HIV-1 Integrase Selected with Raltegravir or Elvitegravir Confer Reduced Susceptibility to a Diverse Panel of Integrase Inhibitors - (06/19/08)
     
  40. ResisWksp: Integrase Inhibitor Resistance (elvitegravir/raltegravir) Involves Complex Interactions Among Primary and Secondary Resistance Mutations: A Novel Mutation L68V/I Associates with E92Q and Increases Resistance - (06/19/08)
     
  41. THERATECHNOLOGIES REPORTS POSITIVE 26-WEEK RESULTS FOR ITS SECOND TESAMORELIN PHASE 3 TRIAL - (06/19/08)
     
  42. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/19/08)
     
  43. ResisWksp: HIV DNA Viral Load Evolution under a Raltegravir-based Therapy: modest decline, authors say "these findings suggest raltegravir may be protective from infection to newly CD4 cells generated during treatment" - (06/19/08)
     
  44. ResisWksp: Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance - (06/18/08)
     
  45. ResisWksp: Virco Etravirine Clinical Cutoffs - (06/18/08)
     
  46. ResisWksp: Monogram HIV-1 Genotype Algorithms for Prediction of Etravirine Susceptibility: Novel Mutations and Weighting Factors Identified Through Correlations to Phenotype - (06/18/08)
     
  47. ResisWksp: Merck's Longitudinal Analysis of Resistance to the HIV-1 Integrase Inhibitor Raltegravir: Results from P005 a Phase 2 Study in Treatment Experienced Patients - (06/18/08)
     
  48. ResisWksp: Mechanism by which the HIV Integrase Active Site Mutation N155H Confers Resistance to Raltegravir - (06/18/08)
     
  49. ResisWksp: Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24 results of the DUET-1 and DUET-2 trials - (06/17/08)
     
  50. ResisWksp: Biological and Clinical Cutoff Analyses for Etravirine in the PhenoSense HIV Assay - (06/17/08)
     
  51. ResisWksp: Monogram Devises Weighted Genotypic Score to Predict Etravirine Response - Written by Mark Mascolini - (06/17/08)
     
  52. ResisWksp: Low-End Clinical Cutoff Proposed for Etravirine - Written by Mark Mascolini - (06/17/08)
     
  53. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/16/08)
     
  54. ResisWksp: Low-Level Pretreatment NNRTI Mutation May Imperil Virologic Response - Written by Mark Mascolini - (06/16/08)
     
  55. ResisWksp: Impact of Raltegravir on HIV DNA--and Fitness of Raltegravir-Resistant Virus - Written by Mark Mascolini - (06/16/08)
     
  56. ResisWksp: Gene-Based Tools Getting Better at Predicting Coreceptor Use - Written by Mark Mascolini - (06/16/08)
     
  57. ResisWksp: Multidrug Resistance in Antiretroviral Therapy-Experienced Patients in North America: 2000-2005 - (06/16/08)
     
  58. ResisWksp: Early Clues From Raltegravir Failure in Clinical Practice; Diverse Patterns of Resistance Mutations - Written by Mark Mascolini - (06/16/08)
     
  59. ResisWksp: HIV-1 Gag Polymorphisms Determine Treatment Response to Bevirimat (PA-457) (06/16/08)
     
  60. ResisWksp: Response to Vicriviroc in HIV-Infected Treatment-Experienced Subjects using an Enhanced Version of the Trofile HIV Co-receptor Tropism Assay: Reanalysis of ACTG5211 Results. Using Enhanced Tropism Assay Improves Outcomes. (06/16/08)
     
  61. ResisWksp: Early Hints on Potency and Cross-Resistance With New NNRTI - Written by Mark Mascolini - (06/13/08)
     
  62. ResisWksp: Hexadecyloxypropyltenofovir (CMX157) has enhanced potency in vitro against NRTI-resistant HIV relative to tenofovir and a favorable preclinical profile - (06/13/08)
     
  63. ResisWksp: Hexadecyloxypropyl Tenofovir (CMX157) Has Enhanced Potency in Vitro against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  64. ResisWksp: Hexadecyloxpropyl Tenofovir (CMX157) Has Enhanced Potency In Vitro Against NRTI Resistant HIV Relative to Tenofovir and a Favorable Preclinical Profile (06/13/08)
     
  65. ResisWksp: New Trofile Assay Would Have Improved Vicriviroc Response in ACTG 5211 - Written by Mark Mascolini - (06/13/08)
     
  66. ResisWksp: Cumulative Resistance Catalog Gives Clearer Picture of Salvage Picks - Written by Mark Mascolini - (06/13/08)
     
  67. ResisWksp: Supersensitive Genotyping Spots More Mutations in Lopinavir Monotherapy Trial - Written by Mark Mascolini - (06/13/08)
     
  68. ResisWksp: Intensifying Standard Regimens Does Not Lower Residual Plasma HIV RNA - Written by Mark Mascolini - (06/11/08)
     
  69. ResisWksp: Triple-Class Resistance Halved in Catalonia From 2002 to 2005 - Written by Mark Mascolini - (06/11/08)
     
  70. ResisWksp: Resistance Mutation Rate Rising in Treatment-Naive US Trial Enrollees - Written by Mark Mascolini - (06/11/08)
     
  71. ResisWksp: Resistance Risk Higher in Injecting Drug Users, Regardless of Adherence - Written by Mark Mascolini - (06/11/08)
     
  72. ResisWksp: Multiclass Resistance Rate--But Not All-Class Resistance--Falls in US and Canada - Written by Mark Mascolini - (06/11/08)
     
  73. ResisWksp: Novel Integrase Mutation Boosts Resistance to Elvitegravir and Raltegravir - Written by Mark Mascolini - (06/11/08)
     
  74. ResisWksp: Five Mutations Tied to Better Tipranavir Response at 48 Weeks - Written by Mark Mascolini - (06/11/08)
     
  75. ResisWksp: NNRTI Mutation Rates With Failing EFV vs NVP in EuroSIDA - Written by Mark Mascolini - (06/11/08)
     
  76. ResisWksp: In Vitro Cross-Resistance Profile for a Next-Generation NNRT I: IDX899 (06/11/08)
     
  77. ResisWksp: Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects (06/11/08)
     
  78. ResisWksp: In Vitro Cross-Resistance Profile, Antiviral Activity, Safety and Pharmacokinetics in HIV-1 Infected Subjects of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance (06/11/08)
     
  79. ResisWksp: Mutually Exclusive Resistance Paths Seen With Raltegravir Failure - Written by Mark Mascolini - (06/11/08)
     
  80. ResisWksp: Q148 Mutations Emerge as Primary Raltegravir Resistance Pathway - Written by Mark Mascolini - (06/11/08)
     
  81. ResisWksp: Routes to Cross-Resistance With Raltegravir and Elvitegravir - Written by Mark Mascolini - (06/11/08)
     
  82. Effects of Early, Abrupt Weaning for HIV-free Survival of Children in Zambia - (06/11/08)
     
  83. Breast-Feeding, Antiretroviral Prophylaxis, and HIV - (06/11/08)
     
  84. Heroin Use Higher Among Hispanic Students: drugs, sex, life-style among students and ethnic disparities - (06/11/08)
     
  85. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy - (06/11/08)
     
  86. Intensive Glycemic Control in the ACCORD and ADVANCE Trials EDITORIAL - (06/11/08)
     
  87. Glycemic Targets and Cardiovascular Disease EDITORIAL - (06/11/08)
     
  88. Effects of Intensive Glucose Lowering in Type 2 Diabetes - (06/11/08)
     
  89. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes - (06/11/08)
     
  90. Delayed Immune-Mediated Adverse Effects of Polyalkylimide Dermal Fillers - (06/09/08)
     
  91. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay - (06/09/08)
     
  92. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies - (06/09/08)
     
  93. Brain chemical serotonin helps us tolerate foul play and appears to cause aggressive angry behavior response - (06/09/08)
     
  94. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/04/08)
     
  95. Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Heterosexual Men - (06/04/08)
     
  96. BRIEF REPORT Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects - (06/04/08)
     
  97. Regional Brain Abnormalities Associated With Long-term Heavy Cannabis Use - (06/03/08)
     
  98. Resurgent HIV Among Men Who Have Sex With Men: What is to be done? Microbicides and Pre-Exposure Prophylaxis is the Only Answer - (06/03/08)
     
  99. Increased Risk of CKD among Type 2 Diabetics with Nonalcoholic Fatty Liver Disease - (06/02/08)
     
  100. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus - (06/02/08)
     
  101. Regional Adipose Tissue and Elevations in Serum Aminotransferases in HIV-Infected Individuals - (05/30/08)
     
  102. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/29/08)
     
  103. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/29/08)
     
  104. 41% of HIV+ MSM in UK Unaware of Status: Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK - (05/29/08)
     
  105. New Option for HIV Testing Now Available - (05/29/08)
     
  106. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/29/08)
     
  107. Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data - (05/28/08)
     
  108. Incidence of Types of Cancer among HIV-Infected Persons Compared with the General Population in the United States, 1992-2003 - (05/28/08)
     
  109. Early Intensive Insulin Therapy for Newly Diagnosed Diabetes - (05/28/08)
     
  110. Inflammation, Lipids and Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies - (05/28/08)
     
  111. New HIV Vaccine Research Funding, Where is Money for USA Needs - (05/28/08)
     
  112. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study - (05/28/08)
     
  113. Lifestyle intervention, diabetes, and cardiovascular disease EDITORIAL - (05/28/08)
     
  114. The global challenge of diabetes, Editorial - (05/28/08)
     
  115. Diabetes care for south Asian patients: a special case, EDITORIAL - (05/28/08)
     
  116. Flavanol-Rich Cocoa: A Promising New Dietary Intervention to Reduce Cardiovascular Risk in Type 2 Diabetes? EDITORIAL COMMENT - (05/28/08)
     
  117. Sustained Benefits in Vascular Function Through Flavanol-Containing Cocoa in Medicated Diabetic Patients - (05/28/08)
     
  118. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study - (05/28/08)
     
  119. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy in The Netherlands - (05/28/08)
     
  120. Pioglitazone in chronic hepatitis C with Insulin Resistance not responding to pegylated interferon-β and ribavirin - (05/27/08)
     
  121. Liver and heart: A new link? - ALT Predicts Heart Disease - (05/27/08)
     
  122. Bioavailability of Generic Ritonavir and Lopinavir/ritonavir Tablet Products in a Dog Model - (05/27/08)
     
  123. Controversies in Hypertension: diet, exercise Weight Loss and Blood Pressure Control (Pro) - (05/27/08)
     
  124. Sex, drugs, and HIV/AIDS in China - (05/27/08)
     
  125. Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial - (05/22/08)
     
  126. Acute Meningoencephalitis in Chronic HIV Infection: Clinical Resolution with Lopinavir-Ritonavir-Containing Therapy - (05/21/08)
     
  127. Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults - (05/21/08)
     
  128. Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults - (05/21/08)
     
  129. Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans - (05/21/08)
     
  130. Use of Multiple Biomarkers to Improve the Prediction of Death from Cardiovascular Causes - (05/19/08)
     
  131. Biomarkers in Heart Failure EDITORIAL - (05/19/08)
     
  132. Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. ACTG 5142 Efavirenz v Kaletra v Efavirenz+Kaletra - (05/19/08)
     
  133. ACTG 5142, Efavirenz v Kaletra v Kaletra+Efavirenz Class Sparing Study. Initial Treatment for HIV Infection - An Embarrassment of Riches EDITORIAL - (05/19/08)
     
  134. Chronic Kidney Disease Incidence, and Progression to End-Stage Renal Disease, in HIV-Infected Individuals: A Tale of Two Races - (05/19/08)
     
  135. HIV and the Kidney: A Spotlight on Racial Disparities EDITORIAL COMMENTARY - (05/19/08)
     
  136. FDA Approves Generic Nevirapine - (05/19/08)
     
  137. New Darunavir 600 mg Tablet Available - (05/19/08)
     
  138. Viracept Use in Pregnancy- Important News - (05/19/08)
     
  139. GSK Response Letters to Abacavir Article in the The Independent - (05/15/08)
     
  140. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. - (05/10/08)
     
  141. Comparative Efficacy between therapies for bone disease: What We Know, What We Need to Know, and How We Can Get There EDITORIAL - (05/10/08)
     
  142. Guidelines Recommend Screening for Men at Increased Risk for Ostoeporosis. "Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians" - (05/10/08)
     
  143. Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? [RESEARCH LETTERS] - (05/07/08)
     
  144. HAART Can Eliminate HIV Mother-To-Child Transmission (MTCT). Properly Timed Effective Use of HAART Can Prevent MTCT - (05/07/08)
     
  145. Bone health & Antiepileptic Drugs - (05/02/08)
     
  146. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy - (05/02/08)
     
  147. Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid-Lowering Drugs in HIV-Infected Individuals and Impact on Myocardial Infarction - (05/02/08)
     
  148. EASL: NAFLD AND NASH Linked to Metabolic Syndrome and Cardiovascular Disease - (05/02/08)
     
  149. Use of Alendronate and Risk of Incident Atrial Fibrillation in Women - (05/01/08)
     
  150. Diabetes drugs (glitazones) double fracture risk: Swiss study - (05/01/08)
     
  151. EASL: NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH HIGHER OVERALL MORTALITY AND LIVER RELATED MORTALITY - (04/25/08)
     
  152. EASL: NEW HCV DRUGS at EASL Apr 23-27, 2008 Milan - (04/23/08)
     
  153. EASL: Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008 - (04/23/08)
     
  154. EASL: HCV Drug Resistance - (04/23/08)
     
  155. The 3rd International Workshop on Clinical Pharmacology of Hepatitis Therapy - Written by Jennifer J. Kiser, Pharm.D. - (04/22/08)
     
  156. 9th International Workshop on Clinical Pharmacology of HIV Therapy - Written by Jennifer J. Kiser, Pharm.D. and Courtney V. Fletcher, Pharm.D. (04/22/08)
     
  157. Insulin Resistance Confounds Heart Disease Studies in HIV: Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy - (04/22/08)
     
  158. CD4 Count & Viral Load Predict non-AIDS & AIDS diseases: CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection - (04/22/08)
     
  159. Major Clinical Outcomes in Antiretroviral Therapy (ART)-Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study - (04/21/08)
     
  160. Inferior Clinical Outcome of the CD4+ Cell Count-Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV RNA Levels during Follow-up - (04/21/08)
     
  161. Hepatic steatosis in HIV/HCV co-infected patients: Correlates, efficacy and outcomes of anti-HCV therapy: A paired liver biopsy study - (04/21/08)
     
  162. CROI: Women, Younger Age & Black Race Associated with Shorter Time to Viral Failure: Effect of Baseline Characteristics on Treatment Outcomes in ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection - (04/21/08)
     
  163. DASH Diet Reduces Heart Disease Risk by 24% - (04/18/08)
     
  164. The Impact of HIV Tropism on Decreases in CD4 Cell Count, Clinical Progression, and Subsequent Response to a First Antiretroviral Therapy Regimen. - (04/18/08)
     
  165. Gut (liver), inflammation and osteoporosis: basic and clinical concepts - (04/16/08)
     
  166. SCHERING-PLOUGH INITIATES PHASE II STUDY WITH VICRIVIROC IN TREATMENT-NAIVE HIV-INFECTED PATIENTS: Novel Nucleoside-Sparing Regimen Designed to Avoid Risk of Toxicity Associated with Nucleoside Class of HIV Drugs - (04/15/08)
     
  167. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2 - (04/15/08)
     
  168. 9th Int Wrkshp Pharm HIV: Safety, Tolerability and Activity of KP-1461 a Novel Viral Mutagen in HIV Infected Adults - (04/15/08)
     
  169. Walking and primary prevention: a meta-analysis of prospective cohort studies - (04/14/08)
     
  170. Maximal oxygen intake and independence in old age: aorobic exercise adds 12 years of life - (04/14/08)
     
  171. 9th Int Wrkshp Pharm HIV: Does HCV or HBV co-infection influence saquinavir exposure in HIV-infected patients without liver function impairment? - (04/14/08)
     
  172. 9th Int Wrkshp Pharm HIV: The effect of different types of food on the bioavailability of TMC278, an investigational NNRTI - (04/14/08)
     
  173. 9th Int Wrkshp Pharm HIV: Pharmacokinetic/Pharmacodynamic (PK/PD) analyses for Raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients - (04/14/08)
     
  174. 9th Int Wrkshp Pharm HIV: The effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral (ARV)-naive HIV-1-infected patients (04/10/08)
     
  175. 9th Int Wrkshp Pharm HIV: Is Twice-Daily Unboosted Atazanavir 200 mg Worth a Harder Look? (04/10/08)
     
  176. 9th Int Wrkshp Pharm HIV: Black Race and Drug Interactions Affect Nonnucleoside Levels in TDM Analysis (04/10/08)
     
  177. Survey highlights lack of sleep: higher insulin levels; heart disease; inflammation; mental/cognitive disorders - (04/10/08)
     
  178. Sleep and HIV illness. - (04/10/08)
     
  179. Insomnia in HIV Infection: A Systematic Review of Prevalence, Correlates, and Management - (04/10/08)
     
  180. High Prevalence of Insomnia in an Outpatient Population With HIV Infection - (04/10/08)
     
  181. 9th Int Wrkshp Pharm HIV: CASTLE Study: Pharmacokinetics and Inhibitory Quotient of Atazanavir/ritonavir 300/100 mg Once Daily Compared to Lopinavir/ritonavir 400/100 mg Twice Daily, Each in Combination with Fixed Dose Tenofovir-Emtricitabine Once Daily, Are Supportive of 48 Week Efficacy and Safety in HIV-1 Infected, Treatment-Naive Subjects (04/10/08)
     
  182. 9th Int Wrkshp Pharm HIV: Single-Dose Pharmacokinetics of Enteric-Coated Didanosine in Subjects with Hepatic Impairment Compared to Healthy Adult Subjects (04/10/08)
     
  183. 9th Int Wrkshp Pharm HIV: Effect of Atazanavir with and without Ritonavir on the Pharmacokinetics of the CYP2C8 Probe Rosiglitazone in Healthy Subjects (04/10/08)
     
  184. 9th Int Wrkshp Pharm HIV: A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients (04/10/08)
     
  185. 9th Int Wrkshp Pharm HIV: The pharmacokinetic (PK) profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 hours (04/10/08)
     
  186. 9th Int Wrkshp Pharm HIV: Raltegravir Levels Down With Tipranavir and Up With Atazanavir (04/10/08)
     
  187. 9th Int Wrkshp Pharm HIV: Once-Daily Darunavir/Ritonavir Keeps Levels High in Healthy Volunteers - written by Mark Mascolini (04/09/08)
     
  188. 9th Int Wrkshp Pharm HIV: Vicriviroc Troughs Correlate With Response in VICTOR-E1 Salvage Study - written by Mark Mascolini (04/09/08)
     
  189. 9th Int Wrkshp Pharm HIV: Raltegravir Levels May Drop With Lopinavir/Ritonavir - written by Mark Mascolini (04/09/08)
     
  190. 9th Int Wrkshp Pharm HIV: Pharmacokinetic Profile of Darunavir (DRV) Co-Administered With Low-Dose Ritonavir (DRV/r) in Treatment-Experienced Women and Men With HIV Infection: 4-Week Analysis in a Substudy of the GRACE (Gender, Race, and Clinical Experience) Study (04/09/08)
     
  191. 9th Int Wrkshp Pharm HIV: Pharmacokinetics of etravirine (ETR; TMC125) are not affected by sex, age, race, use of enfuvirtide (ENF) or treatment duration in HIV-1-infected subjects; tenofovir and HCV affect levels (04/09/08)
     
  192. 9th Int Wrkshp Pharm HIV: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (04/09/08)
     
  193. 9th Int Wrkshp Pharm HIV: Effect of extrinsic and intrinsic factors on the pharmacokinetics of darunavir/ritonavir in HIV-1-infected patients: results of a randomized, controlled, Phase III study (ARTEMIS) (04/09/08)
     
  194. 9th Int Wrkshp Pharm HIV: Darunavir and Ritonavir Levels in Black and Hispanic Women - Written by Mark Mascolini (04/08/08)
     
  195. 9th Int Wrkshp Pharm HIV: Higher Efavirenz Levels--But No More Toxicity--in Nonwhites vs Whites: EuroSIDA - Written by Mark Mascolini (04/08/08)
     
  196. 9th Int Wrkshp Pharm HIV: Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  197. 9th Int Wrkshp Pharm HIV: Tenofovir, Hepatitis, and Weight Moderately Affect Etravirine Levels - Written by Mark Mascolini (04/08/08)
     
  198. New Abbott Kaletra (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe - (04/08/08)
     
  199. DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's Communication Regarding Abacavir - April 4, 2008 - (04/08/08)
     
  200. HPV in Heterosexuals. Prevalence and factors associated with anal lesions mediated by human papillomavirus in men with HIV/AIDS - (04/08/08)
     
  201. Osteoporosis in Men - (04/07/08)
     
  202. EHDRW: Efficacy of DRV/r in the randomised, controlled, Phase III ARTEMIS trial in treatment-naive, HIV-1-infected patients is independent of HIV-1 subtype (04/07/08)
     
  203. ALT Predicts Mortality & General Health - (04/04/08)
     
  204. Liver transplantation in HIV/HCV co-infected patients remains difficult: strategies to get these patients to earlier transplantation are needed - (04/04/08)
     
  205. Bone Disease in HIV: study finds, heavily pre-treated patients had Vitamin D deficiency & serum marker abnormalities & perhaps serum markers may be better for assessing patient risk than total BMD by DEXA - (04/03/08)
     
  206. EHDRW: One in 10 Genotyped Britons Started Therapy With Resistant HIV - Written by Mark Mascolini - (04/02/08)
     
  207. EHDRW: Resistance Measured by Clinical Cutoff Drops Sharply From 1998 to 2007 - Written by Mark Mascolini - (04/02/08)
     
  208. EHDRW: Identification of mutations predictive of a diminished response to darunavir/ritonavir (refined profile): analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2 (04/02/08)
     
  209. CROI: Metabolic Complications: A CROI 2008 Summary Written by David Alain Wohl, MD - The University of North Carolina - (04/03/08)
     
  210. Mitochondrial Toxicity and HCV Liver Disease Progression in Coinfection - (04/02/08)
     
  211. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration - (04/02/08)
     
  212. Risk of myocardial infarction and nucleoside analogues Comment - (04/02/08)
     
  213. Abacavir and the potential risk of myocardial infarction Correspondence - (04/02/08)
     
  214. EHDRW: Prevalence of Darunavir-Linked Mutations Stays Low After Licensing - Written by Mark Mascolini - (03/31/08)
     
  215. EHDRW: Update on the prevalence of the 2007 darunavir resistance-associated mutations in samples received for routine clinical resistance testing - (03/31/08)
     
  216. EHDRW: Has Pretreatment Genotyping Improved Therapy? Answers From Germany - Written by Mark Mascolini - (03/31/08)
     
  217. EHDRW: Combined protease inhibitor (PI) and NNRTI resistance analysis of the pooled DUET trial: towards a regimen-based resistance interpretation (03/31/08)
     
  218. EHDRW: Virco Proposes Preliminary Biological Cutoffs for Integrase Inhibitors - Written by Mark Mascolini - (03/31/08)
     
  219. EHDRW: More Major Mutations in Newly Diagnosed, Untreated Italian Patients - Written by Mark Mascolini - (03/31/08)
     
  220. Early Communication about an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine) from the FDA, March 27, 2008 - (03/28/08)
     
  221. Osteoporosis and Fractures Missing the Bridge? Commentary - (03/28/08)
     
  222. EHDRW: Nevirapine and Slow Genotyping Raise Risk of Resistance to Etravirine - Written by Mark Mascolini - (03/28/08)
     
  223. EHDRW: People With Subtype A or C May Respond More Rapidly to HAART - Written by Mark Mascolini - (03/28/08)
     
  224. EHDRW: "Historic" Resistance Profile Helps Predict PI and Overall Salvage Failure - Written by Mark Mascolini - (03/28/08)
     
  225. EHDRW: Single Mutations at Raltegravir Failure Suggest Low Resistance Barrier - Written by Mark Mascolini - (03/28/08)
     
  226. EHDRW: Background Drugs and Bad Adherence Explain Most Maraviroc Failures - Written by Mark Mascolini - (03/28/08)
     
  227. EHDRW: Trofile Assay Usually Matches Cell Test in Figuring Coreceptor Use - Written by Mark Mascolini - (03/28/08)
     
  228. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  229. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  230. EHDRW: "Staggering" Did Not Ward Off NNRTI Resistance in SMART Drug Breaks - Written by Mark Mascolini - (03/27/08)
     
  231. EHDRW: Steady Drop in Resistant Virus Rates at Virologic Failure in Italy - Written by Mark Mascolini - (03/27/08)
     
  232. EHDRW: Transmitted AZT/d4T-Resistant Virus Persists Up 4 Years Without Treatment - Written by Mark Mascolini - (03/27/08)
     
  233. EHDRW: Tibotec Refines List of Darunavir-Specific Mutations - Written by Mark Mascolini - (03/27/08)
     
  234. EHDRW: Classic Nonnucleoside Mutations Emerge Upon Etravirine Failure - Written by Mark Mascolini - (03/27/08)
     
  235. EHDRW: Up to Four 'Combined' Darunavir/Etravirine Mutations Needed for Sub-50-Copy Response. New Concept in Resistance: Combined Resistance to Multiple Drugs in Regimen - Written by Mark Mascolini - (03/27/08)
     
  236. Clinical Inertia in the Management of Low-Density Lipoprotein Abnormalities in an HIV Clinic - (03/26/08)
     
  237. Steatohepatitis (fatty liver): Risk factors and impact on disease severity in HIV/hepatitis C virus coinfection - (03/26/08)
     
  238. Pregnancy May Not Protect Against HIV Disease Progression - (03/25/08)
     
  239. Association of antiretroviral therapy with fibrinogen levels in HIV-infection - (03/25/08)
     
  240. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients - (03/25/08)
     
  241. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals - (03/25/08)
     
  242. d4T/3TC/Nevirapine Fixed Dose Generic Approved by FDA - (03/25/08)
     
  243. Merck AIDS Vaccine Failure May Doom Promising Study - (03/25/08)
     
  244. CROI: Bone Disease Is Increased in HIV; Cancer Risk Increases with Age & Immune Deficiency - (03/25/08)
     
  245. CROI: Review of Bone Posters at CROI 2008 - Written by Turner Overton, M.D. - (03/24/08)
     
  246. CROI: HIV and Aging at CROI 2008 - (03/24/08)
     
  247. Randomized Trial of Once-Weekly PTH(1-84) on Bone Mineral Density and Remodeling - (03/20/08)
     
  248. HIV and hepatitis B co-infection in Africa Reflection and Reaction - (03/20/08)
     
  249. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa Review - (03/20/08)
     
  250. CROI: Immunopathogenesis of Hepatic Flares after Initiation of ART in HIV/HBV-co-infected Individuals - (03/19/08)
     
  251. Effects of Alendronate on BMD and Fracture Risk: The FOSIT Study - (03/17/08)
     
  252. Osteopenia: intervention & therapy - (03/17/08)
     
  253. Ten Years' Experience with Alendronate (5, 10 and 20 mg daily) for Osteoporosis in Postmenopausal Women - (03/17/08)
     
  254. HIV Proteins Accelerate Liver Disease; HIV Increases HCV Replication in a TGF-ß1-Dependent Manner - (03/14/08)
     
  255. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy - (03/14/08)
     
  256. CROI: Hepatitis C Viremia following Sustained Virological Response to Pegylated Interferon and Ribavarin in HIV+ Men Who Have Sex with Men-Re-infection or Late Relapse? (03/13/08)
     
  257. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws - (03/14/08)
     
  258. Smoking Increases Bone Loss and Decreases Intestinal Calcium Absorption - (03/14/08)
     
  259. Clinical Use of Serum and Urine Bone Markers in the Management of Osteoporosis - (03/14/08)
     
  260. 10 vs 5 Years of Bisphosphonate Treatment for Postmenopausal Osteoporosis EDITORIAL - (03/14/08)
     
  261. The attainment of peak bone mass: what is the relationship between muscle growth and bone growth? - (03/13/08)
     
  262. Osteoporosis and chronic kidney disease - (03/13/08)
     
  263. Benefit of Low-Fat Over Low-Carbohydrate Diet on Endothelial Health in Obesity - (03/13/08)
     
  264. FDA Issues New Prezista (Darunavir) Label Changes - (03/13/08)
     
  265. Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center - (03/13/08)
     
  266. CROI: Risk for Cardiovascular Disease and Regional Adipose Tissue Depots Among HIV-infected Men and Women in the Study of Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) (03/12/08)
     
  267. CROI: Inflammatory Markers Correlate with Carotid Intima-Media Thickness and Endothelial Activation in HIV-infected Patients (03/12/08)
     
  268. CROI: HIV and the Brain: Report from the 15th Conference on Retroviruses and Opportunistic Infections. - Written by Scott Letendre, J. Allen McCutchan, and Ronald J. Ellis (03/10/08)
     
  269. Bone disorders in chronic liver disease - (03/10/08)
     
  270. Medicare Spending to Surge; Chronic Diseases Increase; Hospitals Express Fear - (03/10/08)
     
  271. Challenges in Using Observational Studies to Evaluate Adverse Effects of Treatment: DAD Study - (03/10/08)
     
  272. CROI: Influence of NRTI Choice and Efavirenz Versus Lopinavir Treatment Options on Lipoatrophy-Associated Adipose Tissue Toxicity: A Longitudinal Study - (03/07/08)
     
  273. CROI: Liver histology and hepatic mitochondrial function in HIV-1-infected patients on antiretroviral therapy with chronic transaminase elevation - (03/07/08)
     
  274. CROI: MELD is the Best Predictor of Pre-transplant Mortality in HIV-infected Liver Transplant Candidates???? NO - (03/07/08)
     
  275. It's More Than a Health Crisis: Economics Fuels HIV/AIDS for Black Americans; what drives the AIDS epidemic? - (03/07/08)
     
  276. CROI: Evaluation of Pregnancy PBMC and Placental MtDNA in HIV-infected, HAART-treated Women, Compared to HIV-uninfected Women - (03/07/08)
     
  277. CROI: Diastolic Dysfunction is Common in Asymptomatic HIV Patients - (03/07/08)
     
  278. CROI: Lipoatrophy and lipohypertrophy are independently associated with hypertension (FRAM): the effect of lipoatrophy but not lipohypertrophy on hypertension is independent of obesity - (03/07/08)
     
  279. CROI: Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis - (03/07/08)
     
  280. CROI: The Effect of Hepatitis C Infection on Metabolic Parameters following Initial Therapy of HIV Infected Subjects with Nucleoside +/- NNRTI Regimens - (03/07/08)
     
  281. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (03/07/08)
     
  282. Hemochromatosis Gene Polymorphisms, Mitochondrial Haplogroups, and Peripheral Lipoatrophy during ART - (03/05/08)
     
  283. Low Testosterone Levels are Common and Associated with Insulin Resistance in Men with Diabetes - (03/05/08)
     
  284. Efavirenz Potent Activity Across all CD4 & Viral Load Levels in Treatment-Naives - (03/05/08)
     
  285. Nevirapine (HSR) Hypersenstivity Reaction Safety & CD4 & Viral Load - (03/05/08)
     
  286. CROI: Endothelial Activation Markers Are Linked to HIV Status and Are Independent of ART and Lipoatrophy - (03/05/08)
     
  287. CROI: Prevalence and Risk Factors in HIV-infected Persons for Echocardiographic Abnormalities in the Era of Modern HAART - (03/05/08)
     
  288. HIV-Associated Lipoatrophy: Letting the Genome Out of the Bottle (Genetic Predisposition & Chronic Inflammation) EDITORIAL COMMENTARY - (03/05/08)
     
  289. US healthcare spending: the next ten years (expected to double) - (03/04/08)
     
  290. Name-based HIV reporting doesn't deter testing - (03/04/08)
     
  291. CROI: HIV-Specific Risk Factors for Nonalcoholic Fatty Liver Still Elusive - Written by Mark Mascolini (03/04/08)
     
  292. Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV-1-Infected Patients - (03/03/08)
     
  293. Human Papillomavirus (HPV) Genotype 84 Infection of the Male Genitalia: Further Evidence for HPV Tissue Tropism? CORRESPONDENCE - (03/03/08)
     
  294. GlaxoSmithKline Comments on Epzicom Data Concerning Epzicom from ACTG Study - (03/03/08)
     
  295. Long-Term Survival and Serious Cardiovascular Events in HIV-Infected Patients Treated With Highly Active Antiretroviral Therapy in VA [Brief Report: Clinical Science] - (03/03/08)
     
  296. The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract - (03/03/08)
     
  297. Effects of HIV & antiretroviral therapy on semen quality - (03/03/08)
     
  298. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study - (03/03/08)
     
  299. Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men - (03/03/08)
     
  300. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom - (03/03/08)
     
  301. New Approach Stops HIV At Earliest Stage Of Infection - (02/28/08)
     
  302. NIAID Modifies HIV Antiretroviral Treatment Study Combination Therapy that Includes ABC/3TC Found Less Effective in Subgroup of Antiretroviral-Naive Individuals - (02/28/08)
     
  303. CROI: Week 4 or 12 Response to PegIFN Predicts Sustained Response With HCV/HIV - Written by Mark Mascolini (02/28/08)
     
  304. Tests of new Tenofovir gel show promise for microbicide for women: phase II study reports safe. Tolerable, acceptable, adherence - (02/27/08)
     
  305. Short-Term Exercise Improves ß-cell Function and Insulin Resistance in Older People with Impaired Glucose Tolerance - (02/27/08)
     
  306. CROI: Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and Tenofovir - (02/27/08)
     
  307. CROI: GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter Peripheral Glucose Disposal in a Healthy Rodent Model System - (02/27/08)
     
  308. CROI: Inefficient Renal Transport of Nucleotide Reverse Transcriptase Inhibitor GS-9148 Indicates Its Low Potential for Nephrotoxicity - (02/27/08)
     
  309. CROI: EVOLUTION OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN HIV-INFECTED PATIENTS: INCIDENCE, CHARACTERISTICS AND PREDICTORS - (02/27/08)
     
  310. CROI: 48-Week Raltegravir Data Confirm Salvage Potency Across Pretreatment Variables - Written by Mark Mascolini - (02/27/08)
     
  311. CROI: Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy - (02/27/08)
     
  312. CROI: Efficacy and Safety of Double-Boosted Saquinavir (SQV)/Lopinavir/Ritonavir (LPV/r) in Nucleoside Pretreated Children at 96 Weeks - (02/26/08)
     
  313. CROI: Darunavir EvaLuation in Pediatric HIV-1-Infected treatment-experienced patients, DELPHI (Trial TMC114-C212) - (02/26/08)
     
  314. CROI: Effects of Diet and Exercise and/or Rosiglitazone on Body Composition and Lipids including Oxidized LDL in HIV+ and HIV- Men and Women - (02/26/08)
     
  315. CROI: Do Lipid Signals Favor Maraviroc Over Efavirenz in Untreated People? - Written by Mark Mascolini - (02/26/08)
     
  316. CROI: New NRTI Apricitabine Versus 3TC in 3TC-Experienced Patients: 24-Week Results - Written by Mark - (02/26/08)
     
  317. CROI: Failure and Resistance Differences Between Darunavir and Lopinavir in TITAN - Written by Mark - (02/26/08)
     
  318. CROI: Pharmacokinetics and Potent Anti-HIV-1 Activity of Amdoxovir Plus Zidovudine in a Randomized Double-blind Placebo-controlled Study - (02/26/08)
     
  319. CROI: New Nucleoside, Amdoxovir (DAPD), Potent When Combined With AZT Written by Mark Mascolini - (02/26/08)
     
  320. CROI: Sustained Treatment With Tesamorelin Needed to Keep Belly Fat Off - Written By Mark Mascolini - (02/26/08)
     
  321. CROI: Limb Fat Loss Must Reach 30% Before Patients and Physicians See It - Written By Mark Mascolini - (02/26/08)
     
  322. CROI: Insufficient Virus Suppression during HAART Is a Strong Predictor for the Development of AIDS-related Lymphoma: German CLINSURV Cohort - (02/25/08)
     
  323. CROI: Immunodeficiency and Risk of AIDS-defining and Non-AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006 - (02/25/08)
     
  324. CROI: Dose Escalation, Safety, Tolerability and Pharmacokinetics of a Novel HIV-1 NNRTI, IDX899 in Healthy Subjects - (02/25/08)
     
  325. CROI: Genotypic Resistance and Phenotypic Cross-Resistance Profile in vitro for a Novel NNRTI: IDX899 - (02/25/08)
     
  326. CROI: Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children - (02/25/08)
     
  327. CROI: New and emerging antiretrovirals, Comparative ART Trials, and when to begin HAART after an OI- now or later - written by David Margolis, MD (02/25/08)
     
  328. Intensive glucose lowering arm of diabetes trial is stopped after excess deaths: ADVANCE study suggests different results - (02/22/08)
     
  329. Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men - (02/22/08)
     
  330. CROI: PF-232798, a Second Generation Pfizer Oral CCR5 Antagonist - (02/22/08)
     
  331. CROI: Risk Factors for Reduced Bone Mineral Density In HIV-Infected Individuals In The Modern HAART Era - (02/22/08)
     
  332. CROI: On-treatment responses at weeks 4 and 12 can be used to predict sustained virologic response rates in HIV HCV co-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (02/22/08)
     
  333. CROI: Incidence Anal Squamous Intraepithelial Lesions (SIL) and Predictors of in the SUN Study after One Year of Follow-up - (02/22/08)
     
  334. CROI: Data on 52-Week Safety and Efficacy of Tesamorelin, a Growth Hormone-releasing Factor Analogue, in HIV-infected Patients with Abdominal Fat Accumulation - (02/22/08)
     
  335. The Impact of Episodic CD4 Cell Count-Guided Antiretroviral Therapy in SMART on Quality of Life - (02/21/08)
     
  336. Abbott Receives FDA Approval for SIMCOR (Niaspan / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management - (02/20/08)
     
  337. CROI: Bone Metabolism in HIV: CROI 2008 Update - written by Todd T. Brown, MD, PhD - (02/21/08)
     
  338. CROI: Steady State Pharmacokinetics and Safety of Atazanavir (ATV) After Treatment with ATV 300 mg/Ritonavir 100 mg (ATV/r) QD + ZDV/3TC During the 3rd Trimester of Pregnancy in HIV+ Women - (02/20/08)
     
  339. CROI: Multicenter, Retrospective Study of Incidence and Predictors of Adverse Events Associated With Nevirapine Use in a Cohort of Pregnant and Nonpregnant Women Treated at 3 Urban HIV Clinics in the United States - (02/20/08)
     
  340. CROI: Risk Factors for for Kidney Disease in EuroSida: Climbing CD4 Count Cuts Risk of Worsening Kidney Function - Written by Mark Mascolini (02/20/08)
     
  341. CROI: Racial Disparity in Kidney Disease At Hopkins: Sharp Racial Disparities in Kidney Trouble and End-Stage Disease in HIV+ Cohort - Written by Mark Mascolini - (02/20/08)
     
  342. CROI: Clinical Pharmacology at CROI 2008: Drug Delivery and Disposition, Drug Interactions, Pharmacogenetics and Applications to Patient Care - written by Courtney V. Fletcher, Pharm.D.(02/20/08)
     
  343. CROI: Co-Receptor Tropism, ENV Genotype, and in vitro Susceptibility to CCR5 Antagonists During Monotherapy Study with INCB9471 - (02/20/08)
     
  344. CROI: An Enhanced Version of the Trofile HIV Co-receptor Tropsim Assay Predicts Emergence of CXCR4 Use in ACTG5211 Vicriviroc Trial Samples - (02/19/08)
     
  345. CROI: Detection of Viral Co-receptor Tropism Changes with a High Sensitivity Phenotypic Assay among HIV-infected Patients with Drug-resistant Viremia - (02/19/08)
     
  346. CROI: Long-acting TMC278, a parenteral depot formulation delivering sustained NNRTI plasma concentrations in preclinical and clinical settings - (02/19/08)
     
  347. CROI: Switching from Combivir [CBV] (AZT/3TC) to Truvada [TVD] (TDF/FTC) Preserves Limb Fat: Results of a DEXA Sub-Study of a 48 Week Randomised Study - (02/19/08)
     
  348. CROI: Lower Noninfectious Disease Rates With HAART in All CD4 Brackets - Written by Mark Mascolini (02/19/08)
     
  349. CROI: Fat Changes Boost Heart Disease and Diabetes Risk in HIV-Infected Men - Written by Mark Mascolini (02/19/08)
     
  350. CROI: HIV & ART Led to Bone Loss (02/19/08)
     
  351. CROI: Worse HIV Control--Not Antiretrovirals--Linked to Low Bone Density in Vancouver; ART risk factor in 2nd study - Written by Mark Mascolini (02/19/08)
     
  352. Persistence of HIV in Gut-Associated Lymphoid Tissue despite Long-Term Antiretroviral Therapy - (02/15/08)
     
  353. Immunity Not Mormalized Despite HAART: Normalization of B Cell Counts and Subpopulations after Antiretroviral Therapy in Chronic HIV Disease - (02/15/08)
     
  354. HIV Persists in the Gut Despite Long-Term HIV Therapy - (02/15/08)
     
  355. Blood and Guts and HIV: Preferential HIV Persistence in GI Mucosa EDITORIAL COMMENTARY - (02/15/08)
     
  356. Major international diabetes study does not confirm increased risk of death reported by US trial - (02/15/08)
     
  357. HLA-B*5701 Screening for Hypersensitivity to Abacavir - (02/14/08)
     
  358. Risks in "improving" control of blood glucose - (02/14/08)
     
  359. Diabetes Study Partially Halted After Deaths - (02/14/08)
     
  360. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/14/08)
     
  361. CROI: Liver Fibrosis in an Outbreak of Acute HCV in HIV-infected MSM; accelerated HCV progression if HIV is contracted before HCV (02/14/08)
     
  362. CROI: Sustained Virological Response to Interferon plus Ribavirin Reduces Liver-related Complications and Mortality in HIV/HCV-co-infected Patients by 9-Fold (02/14/08)
     
  363. CROI: CCR5 Antagonists, Tropism Assays: Entry and Entry Inhibitors at 15th Conference on Retroviruses and Opportunistic Infections 2008 -Written by Eric S. Daar, M.D. (02/14/08)
     
  364. CROI: Kidney - Proteinuria, Glomerular Filtration Rate Reductions, and Associated Factors among HIV-Infected and Uninfected Men in the Multicenter AIDS Cohort Study (MACS) (02/14/08)
     
  365. CROI: Clinical Associations of Extremity Fat Loss from ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Antiretroviral Therapy (ART) of Naive, HIV-1 infected Subjects (02/14/08)
     
  366. CROI: Kaletra Tablets Once vs Twice Daily - Written by Mark Mascolini (02/14/08)
     
  367. CROI: Etravirine With Darunavir Stays Strong Through 48 Weeks in DUET Trials - Written by Mark Mascolini (02/14/08)
     
  368. CROI: Metabolic Syndrome Does Not Up Death Risk in HIV Cohort--But Bad Lipids Do - Written by Mark Mascolini (02/14/08)
     
  369. CROI: SLAM-C Study: Maintenance Therapy in Coinfected (02/12/08)
     
  370. CROI: HLA-B*5701 Screening for Hypersensitivity to Abacavir (02/12/08)
     
  371. CROI: Renal Report by Wyatt/Klotman Mt Sinai (02/12/08)
     
  372. CROI: Multistudy Analysis Shows Enhanced CD4 Gain With CCR5 Antagonists - Written by Mark Mascolini (02/12/08)
     
  373. CROI: Reinfection Explains All MDR/XDR TB Cases With HIV at South African Flashpoint - Written by Mark Mascolini (02/12/08)
     
  374. CROI: Immediate Antiretrovirals During Acute OI Lower Death Risk: ACTG A5164 - Written by Mark Mascolini (02/12/08)
     
  375. CROI: Cardiovascular Risk Markers Greatly Inflate Death Risk in People With HIV; interruptions increase risk - Written by Mark Mascolini (02/12/08)
     
  376. CROI: Still Hard to Prove Therapeutic Benefit With Therapeutic Drug Monitoring - Written by Mark Mascolini (02/12/08)
     
  377. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/12/08)
     
  378. CROI: Even at Counts Over 350, More CD4s Lower Death Risk in Untreated HIV+ People (02/12/08)
     
  379. CROI: Resistance After First Failure Looms as Larger Problem in Poor vs Rich Countries (02/12/08)
     
  380. CROI: Faster Death May Be the Price Paid for Delayed Switching After Failure (02/12/08)
     
  381. CROI: Abacavir (But Not Efavirenz) Weaker in Cohort Study Than in Clinical Trial (02/12/08)
     
  382. CROI: Maraviroc 48-Weeks Safety, Efficacy in Treatment-Experienced MOTIVATE 1 and 2 Study Pooled Analysis (02/12/08)
     
  383. CROI: Clinical Study Demonstrates Similar Effectiveness Of Once-Daily vs. Twice-Daily Dosing of Abbott's Kaletra(lopinavir/ritonavir) Tablet in HIV-Infected Patients New to Antiretroviral Therapy. Abbott press release (02/08/08)
     
  384. CROI: A phase I study to explore the activity and safety of SCH 532706, a small molecule chemokine receptor-5 (CCR5) antagonist in HIV-1 infected subjects (02/08/08)
     
  385. CROI: Tenofovir Bolsters Response to IFN/RBV in People With HCV/HIV - Written by Mark Mascolini (02/07/08)
     
  386. CROI: Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates (02/07/08)
     
  387. CROI: DUET-1:Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients (02/07/08)
     
  388. CROI: Characterization of virologic failures on darunavir/ritonavir in the randomized, controlled, Phase III TITAN trial in treatment-experienced patients (02/07/08)
     
  389. CROI: This is a BMS press release CASTLE STUDY SHOWED SIMILAR EFFICACY BETWEEN ONCE-DAILY REYATAZ (atazanavir sulfate)/RITONAVIR AND TWICE-DAILY LOPINAVIR/RITONAVIR AT 48 WEEKS IN PREVIOUSLY UNTREATED HIV-INFECTED ADULT PATIENTS (02/07/08)
     
  390. CROI: New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy - Tibotec press release at end of title (02/07/08)
     
  391. CROI: VICRIVIROC DEMONSTRATES POTENT AND SUSTAINED VIRAL SUPPRESSION THROUGH 48 WEEKS OF THERAPY IN TREATMENT-EXPERIENCED HIV-INFECTED PATIENTS (02/07/08)
     
  392. CROI: Vicriviroc in Combination Therapy With an Optimized Antiretroviral Regimen for Treatment-Experienced Subjects: The VICTOR-E1 Trial (02/07/08)
     
  393. CROI: The Effect of Vicriviroc Upon Viral Load in HIV/HCV Co-infected Patients Receiving a Ritonavir-containing Protease Inhibitor Regimen (02/07/08)
     
  394. CROI: Pharmacokinetics and pharmacodynamics of the NNRTI etravirine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: pooled 24-week results of DUET-1 and DUET-2 (02/07/08)
     
  395. CROI: Pharmacokinetic-pharmacodynamic analyses of once-daily darunavir in the ARTEMIS study (02/07/08)
     
  396. CROI: Once-Daily Darunavir Troughs Stay in Active Range for All ARTEMIS Patients - Written by Mark Mascolini (02/12/08)
     
  397. CROI: Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive (02/07/08)
     
  398. CROI: Tropism Change from Screening to Baseline Matters: Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of Maraviroc in Treatment-Naive Patients - Written by Mark Mascolini (02/06/08)
     
  399. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/06/08)
     
  400. CROI: "No Treatment Options" No Longer a Growing Problem in Switzerland - Written by Mark Mascolini (02/06/08)
     
  401. CROI: Firstline Nukes Evaluated: What Makes a First Regimen Work? Answers From 79 Trials and Cohorts - Written by Mark Mascolini (02/06/08)
     
  402. CROI: Even Totally Controlled HIV Linked to Atherosclerosis Risk - Written by Mark Mascolini (02/06/08)
     
  403. CROI: "Elite Controller" Study Suggests No "Harmless" Level of HIV, Lose CD4s Faster - Written by Mark Mascolini (02/06/08)
     
  404. CROI: 48-Week Results from BENCHMRK-2, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  405. CROI: 48-Week Results from BENCHMRK-1, a Phase III Study of Raltegravir (RAL) in Patients Failing Antiretroviral Therapy (ART) with Triple-Class Resistant HIV-1 (02/06/08)
     
  406. CROI: Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naive (ARV) HIV-1 Infected Subjects (02/06/08)
     
  407. CROI: Boosted Atazanavir Noninferior to Lopinavir in Previously Untreated People - Written by Mark Mascolini (02/05/08)
     
  408. CROI: Abacavir & MI (myocardial infarction) Risk in D.A.D Study - Written by Mark Mascolini (02/05/08)
     
  409. CROI: What Explains Maraviroc Failures in the MERIT Trial of Naive Patients? - Written by Mark Mascolini (02/05/08)
     
  410. CROI: Efficacy and Safety of Abacavir/Lamivudine Compared to Tenofovir/Emtricitabine in Combination with Once-Daily Lopinavir/Ritonavir through 48 Weeks in the HEAT Study - (02/05/08)
     
  411. CROI: Abacavir/3TC vs TDF/FTC: The HEAT Study - Written by Mark Mascolini (02/05/08)
     
  412. CROI: Dramatic Drop in Second-Line Antiretroviral Failures Across US and Canada - Written by Mark Mascolini (02/05/08)
     
  413. CROI: Efficacy and Safety of Boosted Once-Daily Atazanavir and Twice-Daily Lopinavir Regimens in Treatment-Naive HIV-1 Infected Subjects CASTLE: 48-Week Results (02/05/08)
     
  414. CROI: Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine and Lamivudine (Combivir) for 48 Weeks to Treatment-naive HIV-infected Patients (02/05/08)
     
  415. CROI: Longer ART Drug Regimen Found to Help Babies Avoid HIV From Breastfeeding in Africa (02/05/08)
     
  416. CROI: Resuming Therapy Can't Reverse Progression Risk With Off-and-On Therapy - Written by Mark Mascolini (01/04/08)
     
  417. ORAL CANCER IN MEN CAUSED BY HPV VIRUS - (02/04/08)
     
  418. CROI: Circumcision Cuts HSV-2 Risk in Ugandan Men and STDs in Their Wives - Written by Mark Mascolini (01/04/08)
     
  419. CROI: Two Schering CCR5 Antagonists Get Spotlight at HIV Conference - Written by Mark Mascolini (01/04/08)
     
  420. CROI: Male Circumcision Challenges in African Study (01/04/08)
     
  421. CROI: Microbicide Protein Identified (01/04/08)
     
  422. CROI: Two New CCR5 Inhibitors, Actually 3 (01/04/08)
     
  423. CROI: Circumcising Men Slows Herpes Spread by 25%, May Reduce HIV Risk (01/04/08)
     
  424. Does Boosted PI Monotherapy Have Future Utility? Kaletra Monotherapy Studies: the OK Study and MONARK Study - (01/30/08)
     
  425. Insulin Resistance Prevents Response to Peinterferon in Coinfection, study reports - (01/29/08)
     
  426. Episodic HAART in SMART Study Has Worse Quality of Life - (01/29/08)
     
  427. When to Start HAART: CD4 <350 & Viral Load >100,000 Increase Risk for AIDS & Death - (01/29/08)
     
  428. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily HAART Regimens in ART-Naive Patients - (01/28/08)
     
  429. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 - (01/28/08)
     
  430. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen - (01/28/08)
     
  431. VAT (belly fat) is Increased in HIV+ Men, New Study Reports - Relation of Body Composition to Body Mass Index in HIV-Infected Patients With Metabolic Abnormalities - (01/28/08)
     
  432. Influence of Cannabis Use on Severity of Hepatitis C Disease - (01/25/08)
     
  433. New Bone Therapy Denosumab vs Fosamax - (01/25/08)
     
  434. Bone Loss 62% in HIV+ - (01/23/08)
     
  435. Factors Associated with Low Bone Mineral Density (BMD) in a Large Cohort of HIV-Infected U.S. Adults - Baseline Results from the SUN Study -CROI 2007 - (01/23/08)
     
  436. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial - (01/23/08)
     
  437. Cardiovascular risks of calcium supplements in women Editorials - (01/23/08)
     
  438. 80% Bone Abnormalities in France Aquitane Cohort, 27% Osteoporosis - (01/23/08)
     
  439. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? - (01/22/08)
     
  440. Carotid Artery Intima-media Thickness in Nonalcoholic Fatty Liver Disease - (01/22/08)
     
  441. Tenofovir/FTC Prevents Vaginal HIV Infection in Mice - (01/22/08)
     
  442. High Prevalence of Anal Human Papillomavirus (HPV) Infection and Anal Cancer Precursors among HIV-Infected Persons in the Absence of Anal Intercourse - (01/22/08)
     
  443. FDA Approves INtELENCE(tM) (etravirine) for HIV Combination therapy; - INtELENCE is the first NNRtI to show antiviral activity in patients with NNRtI-resistant virus - - (01/22/08)
     
  444. FDA Approves New HIV Drug After Priority Review Etravirine tablets used in combination with other antiretroviral agents - (01/22/08)
     
  445. Etravirine (TMC-125) FDA Package Insert in PDF Format - (01/22/08)
     
  446. Emergence of Multidrug-Resistant, Community-Associated, Methicillin-Resistant Staphylococcus aureus (MRSA) Clone USA300 in Men Who Have Sex with Men - (01/15/08)
     
  447. Low Serum Testosterone Caused Fractures, study found - (01/15/08)
     
  448. Statins for people with diabetes Comment - (01/14/08)
     
  449. Statins for all diabetics urged - (01/14/08)
     
  450. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis - (01/14/08)
     
  451. 273 New HIV Host Proteins Discovery Reported HIV Gets By With a Lot of Help From Human Host - (01/14/08)
     
  452. NASH may be trash: causes of NASH - (01/14/08)
     
  453. linolenic acid (PUFAs) & peripheral neuropathy - (01/14/08)
     
  454. Researchers Find Cell Protein That Nips HIV in the Bud: DC-SIGN EFFICIENTLY BLOCKS HIV VIRAL BUDDING - (01/14/08)
     
  455. Non-Hodgkin Lymphoma Rare After HAART - (01/11/08)
     
  456. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves ß-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose - (01/09/08)
     
  457. FDA ALERT: Bisphosphonates Can Cause Severe Musculoskeletal Pain - (01/08/08)
     
  458. "Is there a" The coming problem of HIV-associated Alzheimer's disease??? - (01/08/08)
     
  459. AIDS Patients Face Downside of Living Longer, Need for more Research on Diseases Associated with Aging - (01/07/08)
     
  460. Incidence of Osteonecrosis of the Jaw in Women With Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Pivotal Fracture Trial - (01/04/08)
     
  461. Oral Bispohosphonates (Fosomax) Found To protect Against Osteonecrosis of Jaw in Osteoporosis - (01/04/08)
     
  462. Frequent Occurrence of Chronic Hepatitis B Virus Infection among West African HIV Type-1-Infected Children - (01/03/08)
     
  463. Hepatitis B Virus and HIV Coinfection in Low-Income Countries: Unmet Needs EDITORIAL COMMENTARY - (01/03/08)
     
  464. Tenofovir-Based Rescue Therapy for Advanced Liver Disease in 6 Patients Coinfected with HIV and Hepatitis B Virus and Receiving Lamivudine BRIEF REPORT - (01/03/08)
     
  465. Tenofovir Nephrotoxicity: Focusing Research Questions and Putting Them into Clinical Context EDITORIAL COMMENTARY - (01/02/08)
     
  466. Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy - (01/02/08)
     
  467. MOST WOMEN WITH HIV AND THEIR HEALTH CARE PROVIDERS HAVE NOT DISCUSSED HOW HIV MIGHT AFFECT THEM DIFFERENTLY THAN MEN - (12/28/07)
     
  468. Plasma Levels, Safety, and 60-Week Efficacy of a Once-Daily Double-Boosted Protease Inhibitor Regimen of Atazanavir, Saquinavir, and Ritonavir [Letters to the Editor] - (12/27/07)
     
  469. Infrared Coagulator Treatment of High-Grade Anal Dysplasia in HIV-Infected Individuals: An AIDS Malignancy Consortium Pilot Study - (12/27/07)
     
  470. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term HAART Reach Same Mortality Rates as the General Population - (12/27/07)
     
  471. Darunavir Full Approval & For Naives: Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration - (12/21/07)
     
  472. ISENTRESS(R) (raltegravir) from MSD, First Integrase Inhibitor, Approved by the European Union Commission - (12/21/07)
     
  473. Generic Efavirenz FDA Approved - (12/21/07)
     
  474. Monogram Trofile Assay Superior to Pathway SensiTrop Assay - (12/19/07)
     
  475. Monogram Statement 'Study Reaffirms Superiority of Trofile(TM) Assay' - (12/19/07)
     
  476. BMD in Older Women Predicts Vertebral Fractures; vertebral fractures reduced survival; a single measure of BMD predicted vertebral factures - (12/18/07)
     
  477. GB Virus C Reduced HCV-Liver Disease in HIV/HCV Coinfected - (12/18/07)
     
  478. EUROPEAN COMMISSION APPROVES ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), THE FIRST ONCE-DAILY SINGLE TABLET REGIMEN FOR VIROLOGICALLY SUPPRESSED ADULTS WITH HIV-1 INFECTION - (12/17/07)
     
  479. Predictive factors of vascular intima media thickness in HIV-positive subjects - (12/17/07)
     
  480. HIV and mitochondrial toxicity in children (& adults) - (12/17/07)
     
  481. EU to approve one-pill-a-day treatment for HIV patients - (12/17/07)
     
  482. Low Incidence of Drug Resistance after Virologic Failure in HIV-1 Infected Subjects Randomized to Remain on their Current Protease Inhibitor (PI) or Switched to a Fosamprenavir Regimen for 24 Weeks (ELECT Study) - (12/14/07)
     
  483. Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes - (12/12/07)
     
  484. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes - (12/12/07)
     
  485. Study: 2 thiazolidinediones diabetes drugs raise heart risks - (12/12/07)
     
  486. Active Smoking and the Risk of Type 2 Diabetes, Increased 44% Risk - (12/12/07)
     
  487. Tenofovir/emtricitabine-containing ART is highly effective in controlling chronic HIV/HBV co-infection but treatment should not be interrupted. - (12/12/07)
     
  488. Mortality and morbidity improved following early ART (>350 CD4) initiation in HIV-infected adults in West Africa - (12/12/07)
     
  489. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/12/07)
     
  490. HIV Entry 3rd Wrkshp: Analysis of the Protease Inhibitor/Reverse Transcriptase Inhibitor/Fusion Inhibitor Resistance Pattern of Treatment-emergent CXCR4-using Virus from Six Patients in the MOTIVATE Studies Shows no Evidence of Different Drug Resistance Profiles Being Archived in the CCR5-tropic versus CXCR4-using Populations - (12/11/07)
     
  491. HIV Entry 3rd Wrkshp: A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - written by David Margolis MD, University of North Carolina at Chapel Hill- (12/11/07)
     
  492. HIV Entry 3rd Wrkshp: Viruses Utilizing Both CCR5 and CXCR4 Are Found in 5-13% of Acute HIV-1 Infections - (12/11/07)
     
  493. HIV Entry 3rd Wrkshp: Characterization of Maraviroc Resistance in Patients Failing Treatment with CCR5-Tropic Virus in MOTIVATE 1 and 2 - (12/11/07)
     
  494. Higher Vitamin D Supplements Advised for Older Black Women - (12/11/07)
     
  495. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C - (12/11/07)
     
  496. A band of optimists considers the road towards a distant goal: eradication; Report from HIV Eradication Conference, 3rd Intl Workshop on HIV Persistence during Therapy, West Indies, St Maartin - (12/11/07)
     
  497. BMS/Gilead ATRIPLA Commercialization in Europe - (12/11/07)
     
  498. HIV Entry 3rd Wrkshp: Low Sensitivity of Gene-Based Tools in Predicting Coreceptor Use - Written by Mark Mascolini - (12/09/07)
     
  499. HIV Entry 3rd Wrkshp: Correlates of Coreceptor Tropism in Three Large Cohorts: Does lower CD4 predict tropism switch? - Written by Mark Mascolini - (12/09/07)
     
  500. HIV Entry 3rd Wrkshp: CXCR4-Using HIV Found in 8.5% During Early HIV Infection - Written by Mark Mascolini - (12/09/07)
     
  501. HIV Entry 3rd Wrkshp: New More Sensitive Monogram Tropism Assay; Tweaked Trofile Assay Stronger in Spotting Dual/Mixed-Tropic Virus - Written by Mark Mascolini - (12/09/07)
     
  502. HIV Entry 3rd Wrkshp: Maraviroc Failure With X4 Virus Does Not Spur New Resistance to Other ARVs - Written by Mark Mascolini - (12/09/07)
     
  503. HIV Entry 3rd Wrkshp: Enhancements to the Trofile HIV Co-receptor Tropism Assay Enable Improved Detection of CXCR4-using Subpopulations and Earlier Detection of CXCR4-using Viruses in Sequential Patient Samples - (12/09/07)
     
  504. HIV Entry 3rd Wrkshp: Background Drugs and Low Maraviroc Levels Explain Resistance in MOTIVATE - Written by Mark Mascolini - (12/09/07)
     
  505. HIV Entry 3rd Wrkshp: Preclinical Work Suggests Advantages of New Fusion Inhibitor Versus Enfuvirtide - Written by Mark Mascolini - (12/09/07)
     
  506. Risk of extensive virological failure to the three original ART drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study - (12/07/07)
     
  507. Screening for diabetes and prediabetes COMMENTARY - (12/07/07)
     
  508. Metabolic Effects of a Growth Hormone-Releasing Factor (GHRH) in Patients with HIV - (12/06/07)
     
  509. Manipulation of the Growth Hormone Axis in Patients with HIV Infection EDITORIAL - (12/06/07)
     
  510. Cardiorespiratory Fitness and Adiposity as Mortality Predictors in Older Adults: Cardio fitness predicts mortality better than BMI, fat - (12/06/07)
     
  511. CDC may raise its estimate of annual HIV cases by 50% - (12/04/07)
     
  512. Generic Tenofovir Approved by FDA - (12/04/07)
     
  513. Changes in the DHHS ART Treatment Guidelines for Adults & and Adolescents - (12/04/07)
     
  514. HIV drug resistance 'on the rise' in China - (12/04/07)
     
  515. GSK responds quickly to query Avandia link to osteoporosis - (12/04/07)
     
  516. BRISTOL-MYERS SQUIBB JOINS WITH NJ CHILDREN'S HOSPITAL IN LAUNCHING NEW CENTER FOR IMMUNE SYSTEM DISORDERS AND INFECTIOUS DISEASES INCLUDING HIV/AIDS - (11/30/07)
     
  517. Do HIV/HCV coinfected have worse neurocognitive function - (11/30/07)
     
  518. Racial Differences in Virologic Failure Associated With Adherence and Quality of Life on Efavirenz-Containing Regimens for Initial HIV Therapy: Results of ACTG A5095 - (11/30/07)
     
  519. A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy - (11/30/07)
     
  520. Joint Statement from Drs. Elias Zerhouni, Jack Whitescarver, and Anthony Fauci of the National Institutes of Health on World AIDS Day NIH Announces 2007 World AIDS Day Award Recipients - (11/30/07)
     
  521. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/30/07)
     
  522. EACS: An Open, Randomized, Two-Period, Crossover Study in Two Cohorts to Investigate the Effect of Steady-State TMC125 (etravirine) and the Combination of TMC125/Darunavir/Ritonavir on the Steady-State Pharmacokinetics of Oral Maraviroc in Healthy Subjects - (11/29/06)
     
  523. losing the battle against heart disease, editorial comment - (11/28/07)
     
  524. Heart disease mortality increases for young women 35-44 and negative trend for young men too - (11/28/07)
     
  525. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer - (11/28/07)
     
  526. Low BMD Associated with Both Low & High Trauma Accidents Causing Fractures in HIV-Negatives - (11/28/07)
     
  527. Low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis - (11/28/07)
     
  528. Magic Johnson & Abbott Events in NYC 11/30: Aims to Reduce New HIV Infections Among African-Americans by 50% by 5 Years - (11/28/07)
     
  529. New more sensitive assay to detect drug-resistant HIV - (11/28/07)
     
  530. Baseline Metabolic Syndrome Predicts Diabetes, study finds - (11/28/07)
     
  531. African-Americans at Risk for Kidney Disease - (11/28/07)
     
  532. The Reemerging HIV/AIDS Epidemic in Men Who Have Sex With Men - (11/28/07)
     
  533. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients - (11/28/07)
     
  534. EACS: Low-Level HIV-1 Viral Load Monitoring in Cerebrospinal Fluid: Possible Correlation to Antiretroviral Drug Penetration - (11/27/06)
     
  535. EACS: TMC278, a next-generation NNRTI, demonstrates potent and sustained efficacy in antiretroviral (ARV)-naive patients: Week 48 primary analysis of study TMC278-C204 - (11/27/06)
     
  536. EACS: Lower lipid levels in antiretroviral (ARV)-naive patients receiving the investigational NNRTI TMC278 versus efavirenz (EFV) - (11/27/06)
     
  537. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV - (11/26/07)
     
  538. Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression - (11/26/07)
     
  539. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease Data from the PROactive Study (PROactive 08) - (11/26/07)
     
  540. Dietary Cod Protein Improves Insulin Sensitivity in Insulin-Resistant Men and Women - (11/26/07)
     
  541. Long-Term Predictors of Insulin Resistance Role of lifestyle and metabolic factors in middle-aged men - (11/26/07)
     
  542. EACS: Tipranavir/r (TPV/r) maintains long term virological suppression - Three year follow-up of RESIST - (11/26/06)
     
  543. EACS: Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score - (11/26/06)
     
  544. EACS: Genotypic tipranavir scores as predictors of response - (11/26/06)
     
  545. EACS: Risk Factors for Kidney Complications - Written by Mark Mascolini - (11/20/06)
     
  546. Vitamin D Supplements Appear to Be Associated With Lower Mortality - (11/19/07)
     
  547. EACS: Hepatic profile of tipranavir in treatment experienced HIV-1 infected individuals - (11/19/06)
     
  548. EACS: Linear modeling to estimate the contribution of each drug component of the regimens of highly treatment-experienced patients in RESIST - (11/19/06)
     
  549. EACS: Patients who responded to tipranavir/r (500/200 mg BID) plus new enfuvirtide (ENF) at Week 16 of RESIST studies maintain superior virologic and immunologic outcomes through Week 96; effects of adding 1 new class to potent protease inhibitor in highly treatment-experienced patients - (11/19/06)
     
  550. Merck Integrase raltegravir drug gets positive nod from EU - (11/16/07)
     
  551. Merck HIV vaccine trial data - (11/15/07)
     
  552. Improved cognitive function as a consequence of hepatitis C virus treatment - (11/15/07)
     
  553. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra (lopinavir/ritonavir) Tablet for Pediatric HIV Patients - (11/15/07)
     
  554. Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy - (11/15/07)
     
  555. FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia - (11/15/07)
     
  556. Increase in STDs-CDC Reports Worrisome Trends - (11/15/07)
     
  557. High HIV Rates in MSM in South Florida
    1 in 11 gay white men in Broward County (Ft Lauderdale) has HIV
    1 in 22 gay, bisexual men in Florida has HIV, study says     - (11/15/07)
     
  558. Prevalence of Chronic Kidney Disease in the United States - (11/08/07)
     
  559. EACS: Predictors of New Darunavir Resistance Mutations Upon Darunavir Failure - Mark Mascolini - (11/08/06)
     
  560. End-Stage Renal Disease Prevalence Climbing as Baby Boomers Age (11/07/07)
     
  561. Monogram Obtains Coverage for Trofile(TM) Assay from California ADAP Program (11/07/07)
     
  562. Single-dose tenofovir and emtricitabine for reduction of viral resistance to NNRTIs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial (11/07/07)
     
  563. Reduction of HIV-1 drug resistance after intrapartum single-dos